Effect of Indacaterol on Inspiratory Capacity (IC)

Phase 3 Completed 173 enrolled Novartis Pharmaceuticals

RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive pulmonary disease (COPD). In particular, spirometric timepoints are included to elucidate the peak-IC in a period of approximately 4 hour post inhalation

Timeline

Start: 2009-11
Primary completion: 2011-01
Completion: —

Outcome

Met primary endpoint

paper Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo (p < 0.001). PMID 25280934 ↗

Publications

Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med. 2014 Oct 4;14:158. doi: 10.1186/1471-2466-14-158.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Indacaterol	Other / unclassified	150 ug	Inhaled
Subject	Tiotropium	Other / unclassified	18 ug	Inhaled